CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 19:01:57 24/05/2024 BST | ||
| 5.77 EUR | -0.69% |
|
| Current month | -0.69% | ||
| 1 month | +33.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 5.77 | -0.69% |
| 23/05/24 | 5.81 | -12.24% |
| 22/05/24 | 6.62 | +0.46% |
| 21/05/24 | 6.59 | -6.66% |
| 20/05/24 | 7.06 | +2.62% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 07:01 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV68LU |
| ISIN | DE000VV68LU9 |
| Date issued | 26/09/2022 |
| Strike | 157.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.49 € |
|---|---|
| Lowest since issue | 3.34 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
217.8
USD
Average target price
286.1
USD
Spread / Average Target
+31.33%
- Stock Market
- Certificates
- Certificat
